Better Buy: Exelixis, Inc. vs. Novartis AG

So far, 2018 is turning out to be a disappointing year for big pharma company Novartis AG (NYSE: NVS). Its stock is down a little year to date, although general market anxiety appears to be the primary culprit. But for Exelixis, Inc. (NASDAQ: EXEL), disappointing is too mild of a word. The biotech stock has dropped more than 20%, with most of the decline coming after Exelixis reported Q4 results that didn't meet investors' expectations.